ABSTRACT
Nowadays technics for Helicobacter pylori detection in stools like culture, and PCR, are expensive and difficult to perform. The aim of this study was to evaluate ELISA test efficacy for detection of H. Pylori antigens in stools comparing this results with standarized technics like histology (Giemsa), ureasa test and UBT C 14. 26 patients were evaluated in this study, ages between 15-75 with upper gastrointestinal symptoms; all of them required gastroduodenal endoscopy, status H. Pylori was determined with methods upon mentioned. 24 hours after endoscopy H. Pylori antigens in stools with the technique Premier Platinum Htsa, Elisa were determined. The detection of H. Pylori antigens in stools accurately identified active H. Pylori infection. The performance characteristics of this non-invasive method was similar in sensibility and specificity to conventional tests.
Subject(s)
Antigens, Bacterial/analysis , Feces/microbiology , Helicobacter Infections/diagnosis , Helicobacter pylori/immunology , Immunoenzyme Techniques/methods , Adolescent , Adult , Aged , Enzyme-Linked Immunosorbent Assay/standards , Female , Humans , Male , Middle Aged , Sensitivity and SpecificityABSTRACT
Nowadays technics for Helicobacter pylori detection in stools like culture, and PCR, are expensive and difficult to perform. The aim of this study was to evaluate ELISA test efficacy for detection of H. Pylori antigens in stools comparing this results with standarized technics like histology (Giemsa), ureasa test and UBT C 14. 26 patients were evaluated in this study, ages between 15-75 with upper gastrointestinal symptoms; all of them required gastroduodenal endoscopy, status H. Pylori was determined with methods upon mentioned. 24 hours after endoscopy H. Pylori antigens in stools with the technique Premier Platinum Htsa, Elisa were determined. The detection of H. Pylori antigens in stools accurately identified active H. Pylori infection. The performance characteristics of this non-invasive method was similar in sensibility and specificity to conventional tests.
ABSTRACT
Mediante técnicas de biología molecular (PCR), hemos podido detectar la presencia de HP en el jugo gástrico en la tercera parte (10/31 pacientes - 32,3 por ciento) de los infectados con la bacteria, según determinación histológica. La demostración de la presencia de HP en jugo gástrico permitirá a traves de nuevos estudios mejorar los conocimientos acerca de los mecanismos de diseminación y complementar la metodología diagnóstica.
Subject(s)
Female , Humans , Aged , Middle Aged , Adult , Gastric Juice/microbiology , Gastric Mucosa/microbiology , Helicobacter pylori/isolation & purification , Polymerase Chain Reaction , Azure Stains , Electrophoresis, Agar Gel , Gastric Mucosa/pathology , Helicobacter pylori/genetics , Sensitivity and SpecificityABSTRACT
Mediante técnicas de biología molecular (PCR), hemos podido detectar la presencia de HP en el jugo gástrico en la tercera parte (10/31 pacientes - 32,3 por ciento) de los infectados con la bacteria, según determinación histológica. La demostración de la presencia de HP en jugo gástrico permitirá a traves de nuevos estudios mejorar los conocimientos acerca de los mecanismos de diseminación y complementar la metodología diagnóstica. (AU)
Subject(s)
Comparative Study , Female , Humans , Aged , Middle Aged , Adult , Polymerase Chain Reaction , Gastric Juice/microbiology , Helicobacter pylori/isolation & purification , Gastric Mucosa/microbiology , Azure Stains , Electrophoresis, Agar Gel , Helicobacter pylori/genetics , Sensitivity and Specificity , Gastric Mucosa/pathologyABSTRACT
HP infection is involved in the pathogenesis of several gastroduodenal diseases, as type B chronic gastritis, duodenal and gastric ulcer, MALT lymphoma and gastric cancer. The recent availability of molecular techniques, specifically the PCR, allow us to detect very low amounts of the bacterium. The aim of the study is to evaluate the presence of HP in gastric juice by PCR technique and to correlate this findings with histology (Giemsa) of gastric mucosa. Gastric juice PCR positive findings were found in 10/31 (32.3%) HP positive patients at histology. We concluded that HP in gastric juice is possible to detect by molecular techniques. In our study 32.3% of the patients showed the presence of HP in gastric juice.
Subject(s)
Gastric Juice/microbiology , Gastric Mucosa/microbiology , Helicobacter pylori/isolation & purification , Polymerase Chain Reaction , Adult , Aged , Azure Stains , Female , Gastric Mucosa/pathology , Helicobacter pylori/genetics , Humans , Male , Middle Aged , Sensitivity and SpecificityABSTRACT
UNLABELLED: Botulinum toxin (BoTox) is a potent inhibitor of the release of acetylcholine from terminal nerves and has been used successfully in spastic disorders of skeletal muscle. Its used for the treatment of disorders of gastrointestinal smooth muscle has recently been explored. In this study we evaluated the efficacy of transendoscopic injection of BoTox in 13 symptomatic patients with achalasia G II (Siewert classification) without previous treatment of an ongoing randomized-controlled trial. Patients were blindly randomized to administrate: a) 8OU of BoTox were injected in four quadrants (1 ml in each quadrant-20 U/ml) (n = 8), b) normal saline solution as placebo injected in the same way (n = 5). Patients who did not respond were retreated in an open design with the same schedule of BoTox. BoTox or placebo were injected directly into the lower esophageal sphincter (LES), located by manometric and endoscopic procedures, via sclerotherapy injector. Response to treatment was assessed by changes in symptoms score, weight, LES pressure, barium esophagograms and endoscopy. All determinations were repeated at basal and after 7-30-60 and 90 days of treatment. Post treatment response was considered positive if at one month, 3 of 4 parameters were improved. No evidence of response to BoTox were assessed in 3 patients. At 90 days, 10 patients remain well and data are as follows: (mean +/- SD) symptoms score: (Pre: 3.23 +/- 0.44) (Post: 1.31 +/- 0.95); LES pressure (mmHg) (Pre: 53, 15 +/- 66.31 +/- 7.49); % reduction of esophageal diameter 55% (p < 0.0001) (pair T-test). Relaxation of LES did not change after treatment. There were no side effects related to BoTox injection. CONCLUSIONS: Endoscopic intrasphincteric BoTox injection is safe, simple and effective in the short term treatment for achalasia. Further studies are necessary for evaluation of long term effects.
Subject(s)
Botulinum Toxins, Type A/therapeutic use , Esophageal Achalasia/drug therapy , Neuromuscular Agents/therapeutic use , Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Prospective Studies , Time FactorsABSTRACT
Botulinum toxin (BoTox) is a potent inhibitor of the release of acetylcholine from terminal nerves and has been used succesfully in spastic disorders of skeletal muscle. Its used for the treatment of disorders of gastrointestinal smooth muscle has recently been explored. In this study we evaluated the efficacy of transendoscopic injection of BoTox in 13 symptomatic patients with achalasia G II (Siewert classification) without previous treatment of an angoing randomized-controlled trial. Patients were blindy randomized to administrate: a) 8OU of BoTox were injected in four quadrants (1 ml in each quadrant-20 U/ml) (n=8) normal saline solution as placebo injected in the same way (n=5). Patientes who did not respond were retreated in an open design with the same schedule of BoTox. BoTox or placebe were injected directly into the lower esophageal sphincter (LES), located by manometric and endoscopic procedures, via sclerotherapy injector. Response to treatment was assessed by changes in symptoms score, weight, LES pressure, barium esophagograms and endoscopy. All determinations were repeated at basal and after 7-30-60 and 90 days of treatment. Post treatment response was considered positive if at one month, 3 of 4 parameters were improved. No evidence of response to BoTox were assessed in 3 patients. At 90 days, 10 patients remain well and data are as follows: (X + SD) symptoms score: (Pre: 3.23 + 0.44) (Post: 1.31 + 0.95); LES pressure (mmHg) (Pre: 53,15 + 66.31 + 7.49); per cent reduction of esophageal diameter 55 per cent (p< 0.0001) (pair T-test). Relaxation of LES did not change after treatment. There were no side effects related to BoTox injection. Conclusions: Endoscopic intrasphincteric BoTox injection is safe, simple and effective in the short term treatment for achalasia. Further studies are necessary for evaluation of long term effects.
Subject(s)
Adult , Aged , Female , Humans , Middle Aged , Botulinum Toxins, Type A/therapeutic use , Esophageal Achalasia/drug therapy , Aged, 80 and over , Injections , Prospective StudiesABSTRACT
Botulinum toxin (BoTox) is a potent inhibitor of the release of acetylcholine from terminal nerves and has been used succesfully in spastic disorders of skeletal muscle. Its used for the treatment of disorders of gastrointestinal smooth muscle has recently been explored. In this study we evaluated the efficacy of transendoscopic injection of BoTox in 13 symptomatic patients with achalasia G II (Siewert classification) without previous treatment of an angoing randomized-controlled trial. Patients were blindy randomized to administrate: a) 8OU of BoTox were injected in four quadrants (1 ml in each quadrant-20 U/ml) (n=8) normal saline solution as placebo injected in the same way (n=5). Patientes who did not respond were retreated in an open design with the same schedule of BoTox. BoTox or placebe were injected directly into the lower esophageal sphincter (LES), located by manometric and endoscopic procedures, via sclerotherapy injector. Response to treatment was assessed by changes in symptoms score, weight, LES pressure, barium esophagograms and endoscopy. All determinations were repeated at basal and after 7-30-60 and 90 days of treatment. Post treatment response was considered positive if at one month, 3 of 4 parameters were improved. No evidence of response to BoTox were assessed in 3 patients. At 90 days, 10 patients remain well and data are as follows: (X + SD) symptoms score: (Pre: 3.23 + 0.44) (Post: 1.31 + 0.95); LES pressure (mmHg) (Pre: 53,15 + 66.31 + 7.49); per cent reduction of esophageal diameter 55 per cent (p< 0.0001) (pair T-test). Relaxation of LES did not change after treatment. There were no side effects related to BoTox injection. Conclusions: Endoscopic intrasphincteric BoTox injection is safe, simple and effective in the short term treatment for achalasia. Further studies are necessary for evaluation of long term effects. (AU)
Subject(s)
Adult , Aged , Female , Humans , Middle Aged , Esophageal Achalasia/drug therapy , Botulinum Toxins, Type A/therapeutic use , Prospective Studies , Aged, 80 and over , InjectionsABSTRACT
Systemic sclerosis is a collagen disease with high frequency of oesophageal affection, specially if we use manometry as an evaluation method that has a high rate of clinic complication in high rate of patients. The aim of the study was to evaluate the prevalence of the oesophageal affection through the clinical, radiological, endoscopical and manometrical studies and to compare the results with other authors. Between January 1978 and February 1993, we evaluated 101 patients with different clinical types of scleroderma 89 females and 12 males with ages between 16-83 (mean: 49, 19 years). In order to determine systemic sclerosis diagnosis following Masi Rodman criterion's we found from 101 cases 83 had dysphagia (82.2%) motor 66 (65%) organic 17 (34.7%) GER was seem in 41 cases (40.5%). According to Heitz's radiological classification: I: 26 patients (25%) II: 58 patients (52.4%) III: 19 patients (18.8%) IV: 17 patients (16.9%). In reference to Neschis manometric classification we found II 88 (76%) III 77 (76%) In accordance with endoscopical classification we found I: 16 (15.8%); II: 49 (48.5%); III: 19 (18.8%); IV: 17 (16.9%); Although this motor and organic oesophageal alterations have an evident diagnostic value, they have also been referred in another metabolic and collagen diseases but with lesser frequency than was found in the systemic sclerosis by us.
Subject(s)
Esophageal Diseases/etiology , Scleroderma, Systemic/complications , Adolescent , Adult , Aged , Female , Humans , Male , Middle AgedSubject(s)
Humans , Male , Female , Helicobacter pylori/pathogenicity , Pepsinogen A/analysis , Duodenal Ulcer/etiology , Age Factors , Helicobacter Infections/etiology , Pepsinogen A/metabolism , Sex Factors , Stress, Physiological/complications , Gastric Juice/chemistry , Nicotiana/adverse effects , Duodenal Ulcer/pathologyABSTRACT
La esclerosis sistémica progresiva, es una colagenopatia con alta frecuencia de compromiso esofágico, especialmente si se utiliza la manometría como método de evaluación y que asume elevadas complicaciones clínicas en un alto porcentaje de pacientes. El objetivo fue evaluar la prevalencia del compromiso esofágico a través de la clínica, radiológia, endoscopia, manometría, y comparar los resultados con los de otros autores. Entre enero de 1978 y febrero de 1993, se evaluaron 101 pacientes con distintas formas clínicas de esclerodermia, 89 mujeres y 12 varones de edades entre 16 y 83 años, con X de 49,19 años. Para establecer el diagnóstico de esclerosis sistémica se tomaron en cuenta los criterios establecidos por Masi, Rodnan (1978). De los 101 casos, 83 tuvieron disfagia (82,2 por ciento), motora 66 (65 por cento) orgánica 17(34,7 por ciento). Reflujo gastroesofágico se observó en 41 casos (40,5 por ciento). Según la clasificación radiológica de Heitz: estadio I, 26 pacientes (25 por ciento), estadio II, 58 pacientes (57,4 por ciento), estadio III, 17 pacientes (16,9 por ciento). Endoscópicamente según Gibbs se encontraron: estadío I, 16 pacients (15,8 por ciento), estadío II 49 pacientes (48,5 por ciento), estadío III, 19 pacients (18,8 por ciento) y estadío IV, 17 pacientes (16,9 por ciento). Manometria, según Neschis, observamos 77 pacientes (76//) en estadío II y III. Si bien estas anormalidades motoras y orgánicas esofágicas tienen un valor diagnóstico evidente también han sido referidas en otras colagenopatías y enfermedades metabólicas, que aunque con frecuencia significativamente menor a la hallada por los autores en la esclerosis sistémica progresiva
Subject(s)
Adolescent , Adult , Middle Aged , Humans , Male , Female , Scleroderma, Systemic/physiopathology , Esophagus/physiopathology , Endoscopy, Digestive System , Scleroderma, Systemic/diagnosis , Esophagus , Manometry , Gastroesophageal Reflux/diagnosis , Deglutition Disorders/diagnosisSubject(s)
Humans , Male , Female , Pepsinogen A/analysis , Duodenal Ulcer/etiology , Helicobacter pylori/pathogenicity , Pepsinogen A/metabolism , Duodenal Ulcer/pathology , Helicobacter Infections/etiology , Gastric Juice/chemistry , Nicotiana/adverse effects , Stress, Physiological/complications , Age Factors , Sex FactorsABSTRACT
La esclerosis sistémica progresiva, es una colagenopatia con alta frecuencia de compromiso esofágico, especialmente si se utiliza la manometría como método de evaluación y que asume elevadas complicaciones clínicas en un alto porcentaje de pacientes. El objetivo fue evaluar la prevalencia del compromiso esofágico a través de la clínica, radiológia, endoscopia, manometría, y comparar los resultados con los de otros autores. Entre enero de 1978 y febrero de 1993, se evaluaron 101 pacientes con distintas formas clínicas de esclerodermia, 89 mujeres y 12 varones de edades entre 16 y 83 años, con X de 49,19 años. Para establecer el diagnóstico de esclerosis sistémica se tomaron en cuenta los criterios establecidos por Masi, Rodnan (1978). De los 101 casos, 83 tuvieron disfagia (82,2 por ciento), motora 66 (65 por cento) orgánica 17(34,7 por ciento). Reflujo gastroesofágico se observó en 41 casos (40,5 por ciento). Según la clasificación radiológica de Heitz: estadio I, 26 pacientes (25 por ciento), estadio II, 58 pacientes (57,4 por ciento), estadio III, 17 pacientes (16,9 por ciento). Endoscópicamente según Gibbs se encontraron: estadío I, 16 pacients (15,8 por ciento), estadío II 49 pacientes (48,5 por ciento), estadío III, 19 pacients (18,8 por ciento) y estadío IV, 17 pacientes (16,9 por ciento). Manometria, según Neschis, observamos 77 pacientes (76//) en estadío II y III. Si bien estas anormalidades motoras y orgánicas esofágicas tienen un valor diagnóstico evidente también han sido referidas en otras colagenopatías y enfermedades metabólicas, que aunque con frecuencia significativamente menor a la hallada por los autores en la esclerosis sistémica progresiva (AU)
